Aurobindo Pharma's consolidated net profit down 18.7% at Rs 491 Cr in Q3

Europe revenue in Q3 FY23 was flat YoY at Rs 1,701.2 crore

Pharma sector, Pharmacy, Pharma regulation
Illustration: Binay Sinha
Press Trust of India Hyderabad
2 min read Last Updated : Feb 09 2023 | 10:24 PM IST

Aurobindo Pharma Limited on Thursday said its consolidated net profit for the quarter ended December 31 was down by 18.7 per cent to Rs 491.2 crore against Rs 604.3 crore in Q3FY22.

A press release from the drug maker said revenue from operations during the quarter under discussion was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.

Commenting on the company's performance, K Nithyananda Reddy, Vice-Chairman and Managing Director of the company said "We witnessed an improved momentum backed by recovery across our business verticals and our endeavor is to continuously innovate and differentiate."

In line with the companys commitment to innovate, there is an increase in the investments in Biosimilars. The company aims to sustain the momentum with new launches, improved cost efficiencies and adherence to the highest standards of compliance, supported by strong execution, he further said.

During the quarter, formulation revenue increase by 9.2 per cent YoY to Rs 5,452.5 crore while in Q3 FY23, US revenue increased by 9.3 per cent YoY to Rs 3,001.2 crore and accounted for 46.8 per cent of consolidated revenues.

The drug maker has launched 11 products during the quarter including six injectable products in the US market.

Europe revenue in Q3 FY23 was flat YoY at Rs 1,701.2 crore.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Aurobindo PharmaQ3 resultsPharma sector

First Published: Feb 09 2023 | 9:03 PM IST

Next Story